Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicis Plans To Build On Zyclara After Graceway Acquisition

This article was originally published in The Pink Sheet Daily

Executive Summary

Medicis begins to flesh out plans for the company after the acquisition of Graceway by building the Zyclara franchise and finishing development of the pipeline products.

You may also be interested in...



Valeant Continues Buying Spree With $2.6B Acquisition Of Medicis

The specialty pharma adds to its dermatology portfolio with a proposed acquisition of Scottsdale, Ariz.-based Medicis.

LEO Plays Up Rapid Action Of Picato For Actinic Keratosis

Newly approved plant-based gel works in just a few days of treatment, rather than the weeks required for some competitors.

Newcomer Graceway Acquires 3M’s American Pharmaceutical Business

Headed by former King chief Gregory, the nine-month-old Tennessee pharma gains access to 3M’s immune response modifier platform on which to build a portfolio.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS073131

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel